ArticleScientific reports2026
Baseline and three-month De Ritis ratio and gamma-glutamyltransferase as prognostic biomarkers in metastatic renal cell carcinoma treated with targeted therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver function tests (LFTs)–derived parameters such as the De Ritis ratio (DRR) and gamma-glutamyltransferase (GGT) may reflect tumor biology and systemic inflammation. Thus, we evaluated both baseline and 3-month measurements of LFTs in patients with metastatic renal cell carcinoma (mRCC) receiving first-line targeted therapy (TT). We retrospectively analyzed 264 patients with mRCC treated with first-line TT. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan–Meier and compared using the log-rank test. Associations of clinicopathological variables with PFS and OS were analyzed using univariate and multivariate Cox models. The median PFS and OS times for the cohort were 12.3 months (95% confidence interval [CI]: 10.7–13.8) and 45.6 months (95% CI: 38.4–52.9), respectively. At 3 months, patients with high DRR had inferior PFS (11.5 vs. 13.4 months, p = 0.003) and OS (33.0 vs. 63.0 months, p < 0.001) compared with those with low DRR. Similarly, patients with elevated GGT (> upper limit of normal) demonstrated shorter PFS (10.3 vs. 13.8 months, p < 0.001) and OS (39.4 vs. 55.0 months, p < 0.001). In multivariate analyses, high DRR was an independent predictor of shorter PFS (hazard ratio [HR]: 1.504, 95% CI: 1.126–2.009, p = 0.006) and OS (HR: 2.108, 95% CI: 1.449–3.066, p < 0.001). Elevated GGT was also independently associated with inferior PFS (HR: 1.624, 95% CI: 1.221–2.158, p < 0.001) and OS (HR: 1.661, 95% CI: 1.198–2.303, p = 0.002). Elevated DRR and GGT values at 3 months were independent predictors of inferior PFS and OS in mRCC, underscoring their utility as practical biomarkers that may improve risk stratification in routine clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.